HT
VRTX icon

Headlands Technologies’s Vertex Pharmaceuticals VRTX Stock Holding History

Headlands Technologies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,864
Closed -$11.7M – 886
2025
Q3 		$11.7M Buy
+29,864
New +$12.5M 0.93% 16
2024
Q4 		– Sell
-7,357
Closed -$3.42M – 1629
2024
Q3 		$3.42M Buy
7,357
+2,986
+68% +$1.43M 0.39% 51
2024
Q2 		$2.05M Buy
4,371
+1,956
+81% +$849K 0.22% 94
2024
Q1 		$1.01M Sell
2,415
-2,294
-49% -$970K 0.24% 107
2023
Q4 		$1.92M Buy
4,709
+685
+17% +$253K 0.57% 30
2023
Q3 		$1.4M Buy
+4,024
New +$1.41M 0.69% 31
2023
Q1 		– Sell
-1,480
Closed -$427K – 780
2022
Q4 		$427K Buy
+1,480
New +$451K 0.34% 88

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Headlands Technologies's VRTX Position: Q4 2025 in Review

Headlands Technologies sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 29,864 shares — an estimated $11.7M sold.

Headlands Technologies first reported a position in VRTX in Q4 2022 and held it in 7 quarters. The position peaked at $11.7M in Q3 2025. 1,672 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Headlands Technologies reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Headlands Technologies sold 29,864 Vertex Pharmaceuticals shares in Q4 2025, an estimated $11.7M.
  • Headlands Technologies first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Headlands Technologies's Vertex Pharmaceuticals position peaked at $11.7M in Q3 2025.
  • 1,672 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Headlands Technologies's 13F filing for Q4 2025, filed 13 Feb 2026.